Substance Abuse Disorders

Enveric Biosciences announced it has signed a nonbinding term sheet to out-license a class of novel psilocin prodrugs to MindBio Therapeutics, an agreement that could yield more than $66 million in sales.

As experts raise awareness of the evidence supporting shorter antibiotic therapy for some conditions and the benefits of oral vs. IV-only therapy for others, we wanted to know: What is another ID dogma that should be reevaluated?

The American Association for the Treatment of Opioid Dependence held its annual conference in Baltimore, from Oct. 30, through Nov. 3.

The majority of people with opioid use disorder in the United States are not receiving life-saving medication due to multiple barriers to access, according to a study published in the International Journal of Drug Policy.

HHS has announced nearly $15 million in funding will be granted for rural communities to address psychostimulant misuse and related overdose deaths.

A primary care intervention that consisted of one-on-one counseling and text messages significantly reduced violent behavior, anxiety and substance use among adolescents, data show.

Children with autism spectrum disorder are vulnerable to developing substance use disorder, according to a study published in JAMA Pediatrics.

Patients with hidradenitis suppurativa are more likely to have substance-related disorders as well as psychiatric disorders, according to a presentation at the European Academy of Dermatology and Venereology congress.